Where can I buy Adagraxibu in China?

Adagrasib (Adagrasib) is a small molecule inhibitor of the KRAS G12C mutant protein, which is found in up to 13% of refractory non-small cell lung cancer cases. Adagrasiib received accelerated approval in the United States in 2022 for adult patients with KRAS G12C-mutated non-small cell lung cancer. It is the second small molecule inhibitor approved for this indication (the first was sotoracib).

Adagrasib is available as 200 mg tablets under the brand nameKrazati. The recommended dose is 600 mg orally twice daily until disease progression or unacceptable toxicity. Side effects of adagrasib are common and occur in nearly all patients treated. During treatment with adagrasiib, serum aminotransferase elevations are common, and a subset of patients develop clinically apparent liver injury, which may be severe. Common side effects include diarrhea, nausea and vomiting, decreased appetite, abdominal pain, fatigue, musculoskeletal pain, cough, dyspnea, edema, leukopenia, anemia, renal impairment, hypokalemia, hyponatremia, and elevated transaminases.

Sinceadagrasibthe original drug has not yet been launched in China and is not sold in domestic hospitals or pharmacies. Therefore, patients can only purchase adagrasib through overseas channels. The specifications of the original American version200mg*180 tablets per box are more than 100,000 yuan (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.